View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 17, 2021updated 12 Jul 2022 11:22am

University Hospitals selects GenomOncology platform for trials

University Hospitals Seidman Cancer Center in the US has selected GenomOncology's Precision Decision and GO Connect solutions to streamline the matching of patients to the increasing number of clinical trials and therapies.

University Hospitals Seidman Cancer Center in the US has selected GenomOncology’s Precision Decision and GO Connect solutions to streamline the matching of patients to the increasing number of clinical trials and therapies.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The platform will help University Hospitals to help scale its precision oncology programme and streamlines a complicated process to assist patients and doctors.

University Hospitals selected the new platform as it needed access to all curated biomarker-based and institutional non-biomarker clinical trials.

GenomOncology’s platform also provides the capability to identify cohorts of patients within the institution eligible for clinical trials and novel therapies.

Additionally, it allows University Hospitals to conduct feasibility analysis to launch new clinical trials across all of its locations wholly-owned by Seidman Cancer Center.

University Hospitals Seidman Cancer Center president and scientific director Dr Theodoros Teknos said: “Due to the speed and complexity of genetic and biomarker discoveries, it is virtually impossible for any oncologist to remain current on all the clinical trials and newly approved cancer therapies.

“Through this partnership with GenomOncology, we have leveraged the power of computing to process incredible amounts of data and identify the optimal care for every patient.”

University Hospitals will use GenomOncology’s Precision Decision and GO Connect solutions to efficiently match patients to therapies, as well as relevant, open clinical trials.

The solution will also be used to ingest data from the institutions’ clinical data warehouse and clinical trial matching system and transform it into usable information available within GenomOncology’s Precision Decision product.

University Hospitals will also be able to identify and interact with all therapies and curated clinical trials in a single dashboard, through which users can search for eligible patients at their institution.

The University Hospitals team can also examine their internal database of clinical and molecular profiles of patients to determine the feasibility of opening new clinical trials.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena